Study guide
21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
Key Takeaways Explain This Topic AI
Severe symptomatic hyponatraemia (seizures, coma) is treated with 150 mL of 3% saline over about 20 minutes, repeated as needed, aiming for a rise of about 5 mmol/L; the total correction should not exceed about 10 mmol/L in the first 24 hours to avoid osmotic demyelination.
Hyperkalaemia with ECG changes is treated first with intravenous calcium to stabilise the myocardium, then insulin with glucose and nebulised salbutamol to shift potassium into cells, and finally removal by binders or dialysis.
Hypokalaemia causes U waves, flattened T waves and arrhythmias; intravenous potassium is usually given at no more than 10-20 mmol/h peripherally, with higher rates only through a central line with ECG monitoring.
Magnesium sulphate 2 g intravenously is the treatment for torsades de pointes, and low magnesium makes hypokalaemia resistant to correction.
Hypocalcaemia after parathyroidectomy, thyroidectomy or massive transfusion causes perioral tingling, tetany, Chvostek's and Trousseau's signs, and QT prolongation; treat symptomatic cases with intravenous calcium gluconate.
Last updated: October 2026
- 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
- Sodium and Water
Plasma sodium reflects the balance between sodium and water : most disorders are disorders of water handling. Normal plasma sodium is about 135-145 mmol/L , and plasma osmolality about 275-295 mOsm/kg , estimated as 2 × Na + + glucose + urea 2 \times \text{Na}^+ + \text{glucose} + \text{urea} 2 × Na + + glucose + urea (all in mmol/L).
Hyponatraemia (Below 135 mmol/L)
Assessment:
Confirm hypotonic hyponatraemia (measured osmolality low); exclude hyperglycaemia (translocational) and pseudohyponatraemia (severe hyperlipidaemia or paraproteinaemia with older analysers).
Assess volume status and measure urine osmolality and urine sodium.
- Volume status Urine sodium Causes
- Hypovolaemic Below 30 mmol/L Vomiting, diarrhoea, burns, third-space losses
- Hypovolaemic Above 30 mmol/L Diuretics (especially thiazides), adrenal insufficiency, cerebral salt wasting
- Euvolaemic Above 30 mmol/L SIADH, hypothyroidism, glucocorticoid deficiency
- Hypervolaemic Usually below 30 mmol/L Heart failure, cirrhosis, nephrotic syndrome
Perioperative causes: hypotonic fluids with non-osmotic ADH release, transurethral resection syndrome (absorption of glycine irrigation fluid), thiazides, SSRIs and carbamazepine.
Clinical features: nausea, headache, confusion, seizures, coma and cerebral oedema, especially when the fall is acute (under 48 hours). Premenopausal women and children are at greater risk of encephalopathy.
Treatment (European guidance, 2014):
Severe symptoms (vomiting, seizures, reduced consciousness): 150 mL of 3% saline over 20 minutes , check sodium, and repeat up to two or three times until sodium has risen by about 5 mmol/L .
Limit the total rise to 10 mmol/L in the first 24 hours and 8 mmol/L in each subsequent 24 hours, because rapid correction of chronic hyponatraemia causes osmotic demyelination syndrome (dysarthria, dysphagia, quadriparesis). Lower limits (for example 8 mmol/L in 24 hours) are used for patients at high risk, such as those with alcoholism or malnutrition.
Chronic asymptomatic: treat the cause; fluid restriction for SIADH; stop offending drugs.
If correction is too rapid, re-lowering with 5% glucose and desmopressin can be considered.
Hypernatraemia (Above 145 mmol/L)
Usually caused by water loss without adequate intake (fever, diarrhoea, osmotic diuresis), diabetes insipidus (cranial after head injury or pituitary surgery, or nephrogenic with lithium), or iatrogenic sodium loading (hypertonic saline, sodium bicarbonate).
Diabetes insipidus: large volumes of dilute urine (osmolality below about 300 mOsm/kg) with rising plasma sodium; cranial DI responds to desmopressin.
Correction: replace water deficit gradually (enterally or with 5% glucose), aiming for a fall of no more than about 10-12 mmol/L per day in chronic hypernatraemia to avoid cerebral oedema.
Potassium
Normal plasma potassium is about 3.5-5.3 mmol/L ; about 98% of total body potassium is intracellular. Insulin, beta-2 agonists and alkalosis move potassium into cells; acidosis, cell damage and hyperosmolality move it out.
Hypokalaemia
Causes: diuretics, vomiting, diarrhoea, insulin, beta-2 agonists, alkalosis, hypomagnesaemia, Conn's syndrome, refeeding.
Features: weakness, ileus, arrhythmias, potentiation of digoxin toxicity; ECG shows flattened T waves, ST depression, U waves and a prolonged QU interval.
Treatment: oral replacement when possible; intravenous potassium chloride is usually given at no more than 10-20 mmol/h through a peripheral vein (concentration limits apply). Faster rates (up to about 40 mmol/h) need a central line and continuous ECG monitoring in a critical care setting. Correct magnesium at the same time.
Hyperkalaemia
Causes: renal failure, potassium-sparing diuretics, ACE inhibitors and angiotensin receptor blockers, acidosis, rhabdomyolysis, tumour lysis, reperfusion, massive transfusion of old blood, suxamethonium in susceptible patients, adrenal insufficiency.
Pseudohyperkalaemia: haemolysed samples, high platelet or white cell counts.
ECG progression: peaked T waves, then prolonged PR and flattened P waves, then widening QRS, sine-wave pattern, ventricular fibrillation or asystole.
- Emergency treatment: 1. PROTECT THE HEART: calcium chloride 10% 10 mL or calcium gluconate 10% 30 mL IV
- (works within minutes, lasts 30-60 min; repeat if ECG changes persist)
2. SHIFT POTASSIUM INTO CELLS:
- Insulin 10 units with 25 g glucose IV (falls by about 0.6-1.0 mmol/L in 30-60 min)
- Nebulised salbutamol 10-20 mg (additive)
- Sodium bicarbonate if acidotic
- 3. REMOVE POTASSIUM: binders (sodium zirconium cyclosilicate, patiromer),
- loop diuretics, haemodialysis for refractory cases
- 4. Monitor glucose (hypoglycaemia risk) and potassium
- Calcium
About 45% of plasma calcium is ionised (the active fraction, about 1.1-1.3 mmol/L), 45% is protein-bound (mainly albumin) and 10% is complexed. Total calcium is about 2.2-2.6 mmol/L . Alkalosis increases protein binding and lowers ionised calcium.
Hypocalcaemia
Causes: hypoparathyroidism (after thyroid or parathyroid surgery), vitamin D deficiency, pancreatitis, rhabdomyolysis, citrate from massive transfusion, hypomagnesaemia, sepsis.
Features: perioral and peripheral paraesthesia, muscle cramps, tetany , laryngospasm, seizures, hypotension, QT prolongation ; Chvostek's sign (facial twitching when tapping the facial nerve) and Trousseau's sign (carpal spasm with an inflated blood pressure cuff).
Treatment: symptomatic or severe: calcium gluconate 10% 10-20 mL intravenously over about 10 minutes, then an infusion; calcium chloride delivers about three times as much elemental calcium per mL but is more irritant and is best given centrally. Correct magnesium.
Hypercalcaemia
Causes: primary hyperparathyroidism and malignancy account for about 90%; also thiazides, sarcoidosis, immobilisation.
Features: "bones, stones, abdominal groans and psychic moans": polyuria, dehydration, constipation, confusion, renal stones, short QT .
Treatment: intravenous saline rehydration, then bisphosphonates (zoledronic acid) for malignancy; calcitonin acts quickly but briefly; treat the cause.
Magnesium
Normal plasma magnesium is about 0.7-1.0 mmol/L . Magnesium is a cofactor for Na/K-ATPase and a physiological calcium antagonist.
Hypomagnesaemia: diuretics, alcoholism, diarrhoea, proton pump inhibitors, refeeding. Causes arrhythmias (including torsades de pointes ), tetany, seizures and refractory hypokalaemia and hypocalcaemia.
Treatment: magnesium sulphate 2 g (8 mmol) intravenously over about 10-20 minutes; for torsades de pointes, 2 g over a few minutes.
Hypermagnesaemia: renal failure or magnesium therapy (for example pre-eclampsia). Loss of tendon reflexes (about 4-5 mmol/L), respiratory depression and heart block at higher levels; potentiates neuromuscular blockers. Treat with intravenous calcium and stop the infusion.
Phosphate
Normal plasma phosphate is about 0.8-1.5 mmol/L . Phosphate is needed for ATP and 2,3-diphosphoglycerate.
Hypophosphataemia: refeeding syndrome, alcohol withdrawal, diabetic ketoacidosis treatment, respiratory alkalosis, renal replacement therapy. Severe deficiency (below about 0.3 mmol/L) causes respiratory muscle weakness (failure to wean), cardiac dysfunction, haemolysis and rhabdomyolysis. Replace intravenously in severe cases.
Hyperphosphataemia: renal failure, rhabdomyolysis, tumour lysis; causes hypocalcaemia and metastatic calcification.